120 related articles for article (PubMed ID: 34937590)
1. Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.
Hasebe K; Mohebbi M; Gray L; Walker AJ; Bortolasci CC; Turner A; Berk M; Walder K; Maes M; Kanchanatawan B; Ashton MM; Berk L; Ng CH; Malhi GS; Singh AB; Dean OM
Acta Neuropsychiatr; 2022 Aug; 34(4):220-227. PubMed ID: 34937590
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
[TBL] [Abstract][Full Text] [Related]
3. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
4. Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2).
Husain MI; Cullen C; Umer M; Carvalho AF; Kloiber S; Meyer JH; Ortiz A; Knyahnytska Y; Husain MO; Giddens J; Diniz BS; Wang W; Young AH; Mulsant BH; Daskalakis ZJ
BMC Psychiatry; 2020 Apr; 20(1):173. PubMed ID: 32295565
[TBL] [Abstract][Full Text] [Related]
5. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
[TBL] [Abstract][Full Text] [Related]
6. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.
Zazula R; Husain MI; Mohebbi M; Walker AJ; Chaudhry IB; Khoso AB; Ashton MM; Agustini B; Husain N; Deakin J; Young AH; Berk M; Kanchanatawan B; Ng CH; Maes M; Berk L; Singh AB; Malhi GS; Dean OM
Aust N Z J Psychiatry; 2021 Aug; 55(8):784-798. PubMed ID: 33092404
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response.
Lombardo G; Nettis MA; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Bogdanova A; Sforzini L; Cleare AJ; Young AH; Dazzan P; Mondelli V; Pariante CM
Brain Behav Immun Health; 2022 Dec; 26():100561. PubMed ID: 36467125
[TBL] [Abstract][Full Text] [Related]
8. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response.
Walker AJ; Mohebbi M; Maes M; Berk M; Walder K; Bortolasci CC; Liu ZS; Ng CH; Ashton MM; Berk L; Singh AB; Malhi GS; Dean OM
Brain Behav Immun Health; 2023 Feb; 27():100581. PubMed ID: 36632339
[TBL] [Abstract][Full Text] [Related]
10. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features.
Patas K; Penninx BW; Bus BA; Vogelzangs N; Molendijk ML; Elzinga BM; Bosker FJ; Oude Voshaar RC
Brain Behav Immun; 2014 Feb; 36():71-9. PubMed ID: 24140302
[TBL] [Abstract][Full Text] [Related]
11. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH
Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
[TBL] [Abstract][Full Text] [Related]
13. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.
Dean OM; Maes M; Ashton M; Berk L; Kanchanatawan B; Sughondhabirom A; Tangwongchai S; Ng C; Dowling N; Malhi GS; Berk M
Clin Psychopharmacol Neurosci; 2014 Dec; 12(3):180-8. PubMed ID: 25598820
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor.
Hasebe K; Gray L; Bortolasci C; Panizzutti B; Mohebbi M; Kidnapillai S; Spolding B; Walder K; Berk M; Malhi G; Dodd S; Dean OM
Acta Neuropsychiatr; 2017 Dec; 29(6):337-346. PubMed ID: 28318471
[TBL] [Abstract][Full Text] [Related]
15. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
Trials; 2015 Sep; 16():410. PubMed ID: 26374703
[TBL] [Abstract][Full Text] [Related]
16. Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial.
Kavanagh BE; Williams LJ; Berk M; Turner A; Jackson HJ; Mohebbi M; Kanchanatawan B; Ashton MM; Ng CH; Maes M; Berk L; Malhi GS; Dowling N; Singh AB; Dean OM
Braz J Psychiatry; 2020; 42(1):14-21. PubMed ID: 31116261
[TBL] [Abstract][Full Text] [Related]
17. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial.
Esalatmanesh S; Kashani L; Khooshideh M; Moghaddam HS; Ansari S; Akhondzadeh S
Arch Gynecol Obstet; 2024 Apr; 309(4):1429-1439. PubMed ID: 37097311
[TBL] [Abstract][Full Text] [Related]
19. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Sforzini L; Bogdanova A; Cleare A; Young AH; Pariante CM; Mondelli V
Neuropsychopharmacology; 2021 Apr; 46(5):939-948. PubMed ID: 33504955
[TBL] [Abstract][Full Text] [Related]
20. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
